Figure 1. The 2026 approvals timeline: one dot per new active substance, by month and authority. Solid dots are ...
The Singapore site serves as a core cornerstone of WuXi XDC's commercial manufacturing, spanning approximately 25,000 square meters. The site's BCM3 dual-function production line and DP4 conjugated ...
Accro Bioscience Inc. (Accro Bio), a clinical-stage biotechnology company pioneering the development of novel therapeutics ...
Specialised Therapeutics announced an expansion of its existing partnership with Incyte Biosciences International, an ...
Women in Singapore now have another option to support their cervical health following Human Papillomavirus (HPV) infection, ...
Transformational merger brings together Telix’s commercial precision medicine platform with ITM’s scaled radioisotope ...
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease ...
Expanded Unique Dual Index range enables high-throughput laboratories to quadruple multiplexing capacity while retaining ...
Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final ...
US healthtech company Massive Bio has appointed international business development consultancy Intralink to support its ...
Adjusted net profit rises 37.4% to RMB 1.03 Bn as the ADC-focused CRDMO expands to 328 integrated projects and builds its service backlog to approximately $2 Bn. WuXi XDC Cayman Inc. (the "WuXi XDC" ...
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first viral vector Contract Development and Manufacturing Organisation (CDMO) advises that the Therapeutic Goods Administration (TGA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results